GLP-1 Medicines in Menopause: What Studies Show for Midlife Weight and Metabolic Change

The question arrived in a book-club group chat, between a photo of someone’s new reading glasses and a reminder about parking: “Is anyone else’s doctor talking about the weekly injection for menopause weight?” Within an hour, four women had replied, and three of them had already searched the exact phrase glp-1 and menopause on their phones.

That small scene is playing out everywhere, and there are concrete reasons. As of mid-2025, interest has been pushed by an observational analysis published in the journal Menopause in 2024, which reported that postmenopausal women taking semaglutide alongside hormone therapy lost more weight than those taking it alone. Add a steady stream of celebrity speculation, trial results showing heart benefits, and clinics advertising “midlife packages,” and a diabetes medicine has become a menopause conversation.

What follows is the version that conversation deserves: what the studies measured, who was in them, how strong each finding is, and where the honest answer is still “we do not know yet.”

What changed recently in the glp-1 and menopause conversation

Four dated facts explain why a question about blood sugar medicines turned into a midlife weight debate.

In 2021, the STEP 1 trial published in the New England Journal of Medicine showed that adults with obesity but without diabetes lost an average of about 14.9 percent of body weight over 68 weeks on weekly semaglutide, compared with roughly 2.4 percent on placebo. Nearly three in four participants were women, and the average age was mid-40s, which means a large share were in perimenopause. That detail went largely unnoticed at the time.

In 2022, SURMOUNT-1 reported that tirzepatide, a related medicine that acts on two gut hormones rather than one, produced average losses of up to about 21 percent at the highest studied dose over 72 weeks. Again, women made up the majority.

In 2023, a cardiovascular outcomes trial in more than 17,000 adults with overweight or obesity and established heart disease found about 20 percent fewer heart attacks, strokes and cardiovascular deaths with semaglutide over roughly three years. The medicine stopped being “only” about the scale.

Then came the 2024 analysis in Menopause: a review of medical records from around 100 postmenopausal women treated with semaglutide, in which those also using menopausal hormone therapy lost about 16 percent of body weight at one year versus about 12 percent in those who were not. It was small, not randomized, and widely reported as if it were a trial.

The shift is subtle but real. Two years ago the search question was “do these medicines work?” Now it is “do they work for me, at this stage of life, and do they interact with everything else my body is doing?” The rest of this article takes that question seriously.

What happens to weight and metabolism at menopause?

Menopause is defined as 12 consecutive months without a menstrual period, reached at an average age of 51 in the United States and the United Kingdom. Perimenopause is the transition before it, often lasting four to eight years, when ovarian hormone levels swing unpredictably. Most of what people call “menopause weight gain” begins in those perimenopausal years.

Three things change at once, and it helps to separate them.

First, aging itself. Adults tend to lose roughly 3 to 8 percent of muscle mass per decade after 30, and muscle is metabolically active tissue. Less muscle means fewer calories burned at rest, which is why cohort studies find women gaining on the order of a pound to a pound and a half a year through their 50s regardless of whether they are using hormones.

Second, fat redistribution. Falling estrogen shifts where fat is stored, away from hips and thighs and toward the abdomen. Visceral fat is the fat packed around internal organs, and it behaves differently from the fat under the skin: it releases inflammatory signals and fatty acids directly toward the liver. Imaging studies suggest the share of body fat stored viscerally roughly doubles across the menopause transition, even in women whose total weight barely moves.

Third, sleep and appetite. Night sweats fragment sleep, and short sleep is consistently linked in observational research to higher hunger-hormone levels and more snacking the next day.

The practical upshot, supported by Mayo Clinic and NHS summaries, is that menopause changes body shape more than it changes the number on the scale, and that the number creeps up mostly because of age and lifestyle. That distinction matters for any medicine claiming to “fix” menopause weight, because the mechanism it targets, appetite, is only one of the three levers.

How do GLP-1 medicines actually work in the body?

GLP-1 stands for glucagon-like peptide-1, a hormone your small intestine releases within minutes of eating. Its natural job is short and busy: it tells the pancreas to release insulin when blood sugar is rising, tells the stomach to empty more slowly, and signals the brain’s appetite centers that food has arrived. Then enzymes break it down in a couple of minutes.

A GLP-1 receptor agonist is a laboratory-made molecule shaped like the hormone but engineered to last for days instead of minutes. Semaglutide and liraglutide are GLP-1 agonists. Tirzepatide is a dual agonist, meaning it also activates the receptor for GIP, a second gut hormone involved in fat and sugar handling, which appears to add to the effect.

The appetite effect is the one most people notice. Food noise, the near-constant background thinking about what to eat next, quiets for many users. Meals feel finished sooner. Interest in alcohol often drops, a finding now being studied in its own right. Slower stomach emptying contributes to fullness but also explains the most common side effects, nausea and constipation.

The blood sugar effect is glucose-dependent: insulin release increases only when sugar is high, which is why these medicines on their own rarely cause dangerous low blood sugar in people without diabetes.

In the US and UK, GLP-1 medicines are licensed for type 2 diabetes, for chronic weight management in adults meeting specified body mass index and health-condition criteria, and, for one of them, for reducing cardiovascular risk in adults with heart disease and excess weight. Most are weekly injections; a daily tablet form of semaglutide exists for diabetes. None is licensed for menopause itself, and none acts on estrogen or progesterone. Anything they do for midlife symptoms is downstream of weight, blood sugar and appetite.

What the evidence actually says, graded by strength

Medical evidence comes in tiers. A randomized controlled trial assigns people to treatment or placebo by chance, which is the only design that can prove cause and effect. An observational study watches what happens to people who chose a treatment, and it is vulnerable to confounding: the people who chose it may differ in ways that matter. Expert opinion sits lowest, useful for gaps but not proof. Here is where each claim about GLP-1 medicines and menopause sits.

Claim	What studies show	Strength of evidence
Substantial weight loss in adults with obesity	Average 15 to 21 percent over 68–72 weeks across large trials, versus 2 to 3 percent on placebo	Strong: multiple randomized trials
Works as well in women over 50	Age and sex subgroups lose similar or slightly greater percentages	Moderate: trial subgroups, not menopause-specific trials
Greater loss when combined with hormone therapy	About 16 versus 12 percent at one year in one record review of roughly 100 women	Weak to moderate: single observational study
Fewer hot flashes	No trials; weight loss itself is modestly linked to fewer vasomotor symptoms	Indirect evidence and expert opinion
Preserves muscle during weight loss	Roughly a quarter to two-fifths of lost weight is lean tissue, similar to diet alone	Moderate: body-composition substudies
Protects the heart	About 20 percent fewer major cardiovascular events in people who already had heart disease	Strong, but only in that population
Improves mood	Mixed observational signals; regulators found no causal link to suicidal thoughts	Low: inconsistent observational data

Two honest caveats frame the table. Every large trial excluded people with type 1 diabetes, a history of pancreatitis, or certain thyroid cancers, and most lasted under two years. Menopause status was not recorded as a variable in any of them, so the “menopause” evidence is inferred from age and sex, not measured directly.

GLP-1 for menopause weight gain: does age change the result, and which one is best?

The most reassuring finding for midlife women is also the least exciting: age does not seem to blunt the effect. When trial investigators split participants into age bands, those over 50 and over 60 lost percentages comparable to those in their 30s. Pooled analyses of several semaglutide and tirzepatide trials have also found that women, on average, lose a somewhat greater percentage of body weight than men, possibly because of differences in body size and drug exposure. Nobody has shown that the menopause transition itself makes these medicines work better or worse.

What about the shape question, since menopause moves fat to the abdomen? Imaging substudies show that fat loss on GLP-1 medicines is proportionally greater from visceral stores than from fat under the skin, which is the pattern seen with most meaningful weight loss. The medicine is not targeting the belly; the body simply tends to release visceral fat first.

“Which GLP-1 is best for menopause weight gain?” is one of the top searched questions, and the truthful answer is that no trial has compared them in menopausal women. In a 2025 head-to-head trial in adults with obesity without diabetes, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Liraglutide, an older daily injection, produces smaller average losses, around 5 to 8 percent in its trials. Those are population averages; individual responses range from very little to far more than the mean.

Choosing between them involves far more than the average number: existing diabetes, heart disease, gallbladder or kidney history, how your stomach tolerates each medicine, what is licensed for your situation, and what your insurer or health system covers. That is a clinical judgment, made with your prescriber, not a ranking anyone can give you from a search result.

GLP-1 and hormone therapy: can they be used together?

Menopausal hormone therapy, often called HRT in the UK and MHT in US guidelines, replaces estrogen, usually with a progestogen to protect the uterus, to treat hot flashes, night sweats and genitourinary symptoms. It is not licensed as a weight-loss treatment, and large randomized trials have found it neither causes meaningful weight gain nor produces meaningful weight loss on its own. What it does appear to do is limit the shift of fat toward the abdomen.

The 2024 record review that sparked so many headlines compared postmenopausal women on semaglutide with and without hormone therapy and found a four-percentage-point difference in weight loss at one year in favor of the combination. Laboratory studies offer a plausible mechanism: estrogen seems to amplify GLP-1 signaling in the brain and pancreas in animals. Plausible is not proven. Women choosing hormone therapy may also sleep better, exercise more, or have fewer other health conditions, any of which could explain the gap. A randomized trial would settle it; none has been published.

There is one practical interaction worth knowing. GLP-1 medicines slow stomach emptying, which can change how quickly oral medicines are absorbed. For hormone therapy taken as a tablet, this is theoretical rather than demonstrated, and patches, gels and sprays bypass the stomach entirely. For perimenopausal women relying on oral contraception, however, the tirzepatide labeling specifically advises additional or non-oral contraception for a period after starting and after each dose change, because pregnancy is still possible until menopause is confirmed.

Should anyone start hormone therapy to boost a weight medicine? Current guidelines say no; the decision about hormone therapy rests on menopausal symptoms and individual risk. Should anyone on both be worried? Also no; nothing in the data suggests harm from the combination. Both calls belong with the clinician who knows your history.

Menopause weight loss injections and muscle: the lean-mass problem

Here is the number that should concern midlife women more than any headline about percentages. In body-composition substudies using DEXA scans, the X-ray method that measures fat, muscle and bone separately, between about 25 and 40 percent of the weight lost on GLP-1 medicines was lean tissue, not fat. That proportion is similar to what happens with diet-induced weight loss or bariatric surgery; it is not unique to the medicine. But it lands at a stage of life when muscle and bone are already in decline.

Sarcopenia is the medical term for age-related loss of muscle mass and strength, and it accelerates after menopause because estrogen helps maintain muscle protein. Lose 20 pounds in which 6 are muscle, at 55, without resistance training, and you may end up lighter but weaker, with a lower resting metabolism that makes regain easier.

Bone follows a similar logic. Women can lose up to 10 percent of bone density in the first five years after menopause. Weight loss by any method tends to reduce bone density further, partly because bones adapt to carrying less load. The GLP-1 trials have not shown an increase in fractures, but they lasted one to three years, which is too short to detect fracture risk reliably. Longer follow-up is underway.

The evidence-backed response is unglamorous. Resistance training at least twice a week, enough dietary protein spread across meals, and adequate vitamin D and calcium are the measures shown to preserve lean mass during weight loss in randomized trials of older adults. Several ongoing trials are testing whether structured exercise or protein targets change body composition specifically in people on these medicines. Until they report, treating the prescription as half of a plan, with strength work as the other half, is the position most specialists take.

Do GLP-1 medicines help hot flashes, sleep or mood?

This is where viral claims run furthest ahead of the data, so it pays to go symptom by symptom.

Hot flashes and night sweats. No trial has measured vasomotor symptoms as an outcome of GLP-1 treatment. Indirectly, observational research and one older randomized lifestyle trial found that women who lost weight reported fewer or less bothersome hot flashes, and higher body fat is associated with more frequent symptoms. So weight loss might help some women; the medicine has no demonstrated direct effect on temperature regulation. Anyone whose flushes are disrupting life has evidence-based options, hormonal and non-hormonal, that a clinician can walk through.

Sleep. Obstructive sleep apnea, repeated airway collapse during sleep, becomes much more common after menopause and is often misread as insomnia or “just hormones.” In 2024, two randomized trials showed tirzepatide cut the number of breathing interruptions per hour by roughly half in adults with obesity and sleep apnea, and US regulators approved it for that use in December 2024. For women whose poor sleep is driven by apnea rather than night sweats, that is a meaningful, trial-grade finding.

Mood. Early case reports of low mood and suicidal thoughts prompted formal reviews. In 2024, both the US Food and Drug Administration’s preliminary evaluation and the European Medicines Agency’s safety committee concluded the available evidence did not support a causal link. Observational studies since have pointed in both directions, with some finding lower rates of depression diagnoses in users and others no difference. Weight loss itself can lift mood; so can better sleep. Equally, mood symptoms are common in perimenopause for reasons unrelated to weight. Any new or worsening low mood on these medicines is a reason to contact the prescriber, not to wait it out.

Heart, liver and metabolic health beyond the scale

Cardiovascular disease is the leading cause of death in women, and risk climbs steeply after menopause as blood pressure, LDL cholesterol and triglycerides drift upward. This is the territory where GLP-1 evidence is strongest and most relevant to midlife, provided the fine print is read.

The 2023 cardiovascular outcomes trial enrolled adults aged 45 and older with overweight or obesity who already had a prior heart attack, stroke or peripheral artery disease. Semaglutide reduced the combined rate of cardiovascular death, heart attack and stroke by about 20 percent over roughly 40 months. Just over a quarter of participants were women, and the effect appeared consistent across sexes. The caveat is the population: these were people with established disease. Whether the same protection applies to a healthy 52-year-old with a slowly rising waistline is not yet known, and trials in lower-risk groups are ongoing.

The metabolic markers tell a more universal story. Across the weight-management trials, participants saw average reductions in systolic blood pressure of several points, lower triglycerides, and improvements in HbA1c, the blood test reflecting average glucose over about three months. In STEP 1, a large majority of participants who began with prediabetes returned to normal glucose readings by the end of the study, compared with a minority on placebo.

Liver fat deserves a mention because it rises sharply after menopause. Metabolic dysfunction-associated steatotic liver disease, the newer name for fatty liver not caused by alcohol, improved substantially in trials of semaglutide, with resolution of liver inflammation in a significant share of participants. These benefits track closely with how much weight is lost, which again points to the medicine as a means to an end rather than a direct organ treatment.

Can high cortisol levels contribute to weight gain during menopause?

Cortisol is the body’s main stress hormone, released by the adrenal glands on a daily rhythm that peaks shortly after waking and ebbs through the evening. Social media has turned it into a villain, with “cortisol belly” quizzes and supplements promising to flatten it. The evidence is more interesting and less convenient than that.

Chronically elevated cortisol does favor fat storage around the abdomen; fat cells there carry more cortisol receptors than fat cells on the hips. Observational studies consistently link high perceived stress, short sleep and shift work with larger waist circumference. Several studies of women across the menopause transition have also found a flatter daily cortisol curve, with higher evening levels, particularly in those with frequent night sweats. So the pathway is real: disrupted sleep raises cortisol, cortisol nudges fat toward the middle, and estrogen loss is doing the same thing from a different direction.

What the evidence does not support is the idea that most midlife weight gain is a cortisol disorder that a supplement can correct. Cushing’s syndrome, a true excess of cortisol from a tumor or long-term steroid medicine, is rare and comes with distinctive signs such as easy bruising, a rounded face, purple stretch marks and muscle weakness; it is diagnosed with specific blood, saliva or urine tests, not a home kit. Over-the-counter “cortisol blockers” and adaptogen blends have no randomized trial evidence for weight loss, and the NIH Office of Dietary Supplements rates most such ingredients as unproven.

GLP-1 medicines do not act on cortisol. The interventions with actual trial support for lowering stress-related eating are mundane: protected sleep, regular aerobic exercise, structured stress-reduction programs and limiting alcohol, which raises cortisol and fragments sleep. If stress feels unmanageable, that is a conversation for a clinician, not a supplement aisle.

Side effects midlife women should know about

Most side effects of GLP-1 medicines are gastrointestinal and dose-related. In STEP 1, about 44 percent of participants reported nausea at some point, compared with 17 percent on placebo; diarrhea, constipation and vomiting were also more common. Symptoms typically peak in the first weeks and after each increase, then fade for most people, but roughly 1 in 20 participants in trials left because of them.

Several less common effects deserve specific attention in midlife.

• Gallbladder problems. Rapid weight loss by any method raises the risk of gallstones, and trials recorded more gallbladder events with these medicines than placebo. Pain under the right ribs after meals is the classic sign.
• Pancreatitis, inflammation of the pancreas, occurred rarely but is serious. Severe, persistent abdominal pain radiating to the back is the warning.
• Hair shedding was reported by around 3 percent of participants, usually a temporary pattern called telogen effluvium that follows rapid weight loss and overlaps with the thinning many women notice at menopause anyway.
• Facial volume loss, nicknamed “Ozempic face” online, is simply fat loss from the cheeks and temples. It is more visible after 50 because skin has less collagen to spring back.
• Dehydration and dizziness can follow reduced fluid intake, a particular concern in women already losing fluid through night sweats.
• A boxed warning about thyroid C-cell tumors is based on rodent studies; the medicines are not used in people with a personal or family history of medullary thyroid cancer or a related genetic syndrome.
• For women with diabetes using insulin or certain other medicines, low blood sugar becomes possible and dosing of those medicines may need adjustment by the prescriber.

This is not a complete list, and the formal patient leaflet from MedlinePlus or the NHS is the authoritative source. Anyone experiencing persistent symptoms should raise them with the prescriber rather than adjusting or stopping on their own.

Common myths about glp-1 and menopause, corrected

Myth: menopause weight gain is purely hormonal, so only a hormone can address it. Hormone therapy limits abdominal fat shift but does not produce meaningful weight loss in randomized trials. Age-related muscle loss, sleep disruption and activity changes account for most of the gain, and those respond to the same measures at 55 as at 35.

Myth: GLP-1 medicines target belly fat specifically. They reduce appetite; the body then draws on visceral fat early, as it does with any substantial weight loss. There is no belly-seeking mechanism.

Myth: hormone therapy makes you gain weight. Decades of trial data say otherwise. Women gain weight during the years they are typically offered hormone therapy, and the timing gets blamed on the treatment.

Myth: once you hit your goal you can stop and the weight stays off. In the STEP 1 extension study, participants who stopped semaglutide regained about two-thirds of their lost weight within a year, and metabolic improvements largely reversed. Obesity behaves as a chronic condition. What that means for the length of any individual’s treatment is a decision for the treating clinician, not a reason to continue or stop on your own.

Myth: compounded or online versions are the same product. Compounded GLP-1 preparations are not approved by regulators, have not been tested for safety or consistency, and have been linked to dosing errors and hospital visits. Products sold as “research peptides” are not licensed medicines and are not for human use. Neither is an appropriate route to treatment.

Myth: a celebrity’s menopause “secret” is a treatment plan. No verified medical information exists about what any public figure takes, and if it did, it would tell you nothing about your own heart, thyroid, bones or blood sugar.

Myth: you cannot be on hormone therapy and a GLP-1 medicine together. Nothing in the data suggests harm from the combination; the only established interaction concerns oral contraception absorption with tirzepatide.

How can I lose weight during menopause without medicine, or alongside it?

Whether or not a prescription is part of the picture, the trials that produced those headline percentages all included lifestyle counseling, and the women who maintained results longest were the ones who built habits the medicine could support rather than replace. The following measures have randomized trial evidence in adults over 50.

Strength training is the single highest-yield change at this stage. Two or more sessions a week of progressive resistance work, with weights, bands or body weight, preserves muscle during weight loss and improves bone density modestly. Both the American Heart Association and CDC recommend it alongside 150 minutes of moderate aerobic activity weekly; brisk walking counts.

Protein matters more than it did at 30. Older adults need somewhat more protein per meal to trigger muscle building, and spreading intake across the day, rather than loading it at dinner, performed better in trials of lean-mass preservation.

Sleep is not optional. Treating night sweats, screening for sleep apnea, and keeping a consistent wake time all reduce the next-day appetite effects seen in sleep-restriction studies.

Alcohol deserves a frank look. It adds calories, worsens hot flashes and fragments sleep, and many women find their tolerance drops in perimenopause anyway.

Realistic numbers help. Intensive lifestyle programs such as the Diabetes Prevention Program produced average losses of 5 to 7 percent at one year, and that was enough to cut progression to type 2 diabetes by more than half. Five percent is modest on the scale and substantial for blood pressure, liver fat and joint pain.

None of this is a reason to feel judged if lifestyle alone has not worked. Weight regulation is biological, menopause stacks the deck, and asking a clinician about all the options, including medicine, is a health decision like any other.

When to see a doctor

Two kinds of conversation belong with a clinician: deciding whether a GLP-1 medicine fits your situation, and acting on warning signs if you are already taking one.

Book a routine appointment if midlife weight change is accompanied by new fatigue, hair or skin changes, heavy or irregular bleeding, or persistent low mood; thyroid disease, iron deficiency and depression all become more common around menopause and can mimic or compound weight concerns. A clinician can also assess blood pressure, cholesterol, glucose and, where appropriate, bone density, which are the measures that actually define metabolic risk. Any question about starting, combining, changing or stopping a GLP-1 medicine or hormone therapy belongs in that conversation; please do not adjust a prescribed medicine on your own.

Seek urgent medical care if you are taking a GLP-1 medicine and notice any of the following:

• Severe, persistent abdominal pain, especially if it spreads to your back, with or without vomiting.
• Vomiting or diarrhea so prolonged you cannot keep fluids down, or signs of dehydration such as dizziness on standing and very dark urine.
• Yellowing of the skin or eyes, pale stools or dark urine, or pain under the right ribs after eating.
• A lump or swelling in the neck, new hoarseness, or difficulty swallowing.
• Sudden changes in vision, particularly if you have diabetes.
• Shaking, sweating, confusion or a racing heart suggesting low blood sugar, especially if you also use insulin or similar medicines.
• Swelling of the face, lips or throat, hives, or difficulty breathing, which may signal an allergic reaction.
• Thoughts of harming yourself or a sudden, marked change in mood.

If you are perimenopausal and could become pregnant, contact your prescriber promptly if you suspect pregnancy, because these medicines are stopped before and during pregnancy under medical guidance. Every decision about this treatment, from whether to begin to how long to continue, rests with the clinician who prescribes it and knows your history.

Frequently asked questions

What does Jennifer Aniston use for menopause?

There is no verified medical information about what any celebrity uses for menopause or weight, and speculation online is not evidence. What a public figure is prescribed, if anything, depends on her private medical history and tells you nothing about your own risks. The evidence-based way to evaluate GLP-1 medicines or hormone therapy is through trial data and a conversation with your own clinician.

Is there any evidence on perimenopause and GLP-1 medicines specifically?

Not directly. The large trials recorded age and sex but not menopausal stage, so perimenopausal women are represented, given an average participant age in the mid-40s, but not analyzed as a group. Subgroup data show similar weight loss across age bands. One practical point is specific to perimenopause: pregnancy remains possible, and tirzepatide can reduce oral contraceptive absorption, so contraception should be discussed with the prescriber.

Can high cortisol levels cause weight gain during menopause?

Chronically raised cortisol can favor abdominal fat storage, and observational studies link poor sleep and high stress with larger waist size in midlife women. True cortisol excess, Cushing’s syndrome, is rare and is diagnosed with specific laboratory tests. Over-the-counter cortisol blockers have no trial evidence for weight loss. Sleep, exercise and stress management have the strongest support, and GLP-1 medicines do not act on cortisol.

Which GLP-1 is best for menopause weight gain?

No trial has compared GLP-1 medicines in menopausal women. In a 2025 head-to-head trial in adults with obesity, tirzepatide produced greater average weight loss than semaglutide, and liraglutide produces smaller losses in its trials. Averages hide wide individual variation, and the right choice depends on your health conditions, tolerability and what is licensed for your situation, which is a decision for your prescribing clinician.

Does hormone therapy make GLP-1 medicines work better?

One 2024 observational review found postmenopausal women on both semaglutide and hormone therapy lost about 16 percent of body weight at one year versus 12 percent without hormone therapy. Animal studies suggest estrogen may amplify GLP-1 signaling, but the human finding could reflect differences between the women rather than the hormones. Guidelines do not recommend starting hormone therapy for weight loss; it is prescribed for menopausal symptoms.

Do GLP-1 medicines reduce hot flashes?

No trial has measured hot flashes as an outcome of GLP-1 treatment, so there is no direct evidence. Indirectly, higher body fat is associated with more frequent vasomotor symptoms, and some observational research suggests weight loss modestly reduces them. Any benefit would come through weight change rather than a direct effect on temperature regulation. Proven treatments for hot flashes exist and are worth discussing with a clinician.

What happens to my weight if I stop a GLP-1 medicine?

In the STEP 1 extension study, participants who stopped semaglutide regained about two-thirds of their lost weight within a year, and improvements in blood pressure and glucose largely reversed. This reflects the chronic nature of weight regulation rather than a flaw in willpower. How long any individual continues treatment, and how to approach any change, is a decision to make with the prescriber rather than independently.

Will a GLP-1 medicine make muscle and bone loss worse after menopause?

Body-composition substudies show roughly a quarter to two-fifths of weight lost is lean tissue, similar to diet-induced weight loss, and weight loss by any method lowers bone density slightly. Because muscle and bone already decline after menopause, specialists emphasize resistance training twice weekly, adequate protein and vitamin D during treatment. Trials to date have not shown increased fractures, but follow-up has been short.

Are compounded GLP-1 injections or research peptides safe alternatives?

No. Compounded GLP-1 preparations are not approved by regulators, have not been tested for safety, purity or consistent strength, and have been associated with dosing errors and emergency visits. Products marketed as research peptides are not licensed medicines and are not for human use. The only appropriate route is a prescription for an approved medicine from a clinician who has reviewed your medical history.

Can GLP-1 medicines affect mood during menopause?

Formal reviews by US and European regulators in 2024 found no causal link between GLP-1 medicines and suicidal thoughts, and observational studies on depression are mixed. Weight loss and better sleep can improve mood for some people, while perimenopause independently raises the risk of low mood. Any new or worsening mood symptoms while taking these medicines should be reported to the prescriber promptly rather than waited out.

References

• Cleveland Clinic: GLP-1 Agonists
• MedlinePlus: Semaglutide Injection
• NHS: Menopause

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.